Back to Journals » Cancer Management and Research » Volume 4

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors

Authors Yim K

Received 20 April 2012

Accepted for publication 12 June 2012

Published 31 July 2012 Volume 2012:4 Pages 207—214


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Kein-Leong Yim

Velindre Cancer Center, Cardiff, Wales, United Kingdom

Abstract: Pancreatic neuroendocrine tumors are rare and the majority of patients present in the advanced stage. Over the past few decades, treatment for patients with metastatic well- or moderately differentiated pancreatic neuroendocrine tumors have not significantly impeded tumor progression nor improved survival. However, recent mapping of intracellular signaling pathways promoting tumor proliferation, growth, and angiogenesis has presented mammalian target of rapamycin (mTOR) as a potential target within the phosphatidylinositol 3-kinase-Akt pathway. With the development of the new-generation mTOR inhibitor everolimus, a series of clinical trials over the last 5 years have demonstrated significant benefit in delaying tumor progression. This review focuses on the mechanism of mTOR inhibition and traces the development of clinical evidence for the use of mTOR inhibitors in well- to moderately differentiated advanced pancreatic neuroendocrine tumors.

Keywords: everolimus, mTOR, neuroendocrine, pancreatic, signaling, targeted

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]